Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 7,795

Document Document Title
WO/2019/070169A1
The invention relates to a water-soluble liophilised form of (bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)- (4-nitrophenyl)methane) which has hepatoprotective activity and is designed to be used in medicine for the treatmen...  
WO/2019/062665A1
The present invention discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker drug conjugate. The linker compound and the polyethylene glycol conjugate and a derivati...  
WO/2019/053426A1
There is herein provided a compound of formula (I).  
WO/2019/053494A1
The present invention relates to a process of preparation of O-Desmethyl tramadol through potassium hydroxide mediated demethylation of Tramadol under phase transfer conditions.  
WO/2019/053429A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R 2, R 3, R 4 and n have meanings as provided in the description.  
WO/2019/041961A1
Provided are a transparent nucleating agent, a preparation method therefor and the use thereof, wherein the transparent nucleating agent comprises a compound represented by formula (1) and a derivative thereof; the method comprises: brin...  
WO/2019/035775A1
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation ...  
WO/2019/030194A1
The invention relates to a process for manufacturing polyethyleneannine compounds selected from the group of polyethyleneamines and hydroxyethylethyleneamines comprising the steps of - in an adduction step providing a CO2 adduct of a sta...  
WO/2019/026994A1
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...  
WO/2019/022251A1
A (poly)amine compound represented by formula (0): (in formula (0), RX represents a C1-70 2nA-valent group or a single bond; R1A each independently represent an optionally substituted C1-30 alkyl group, an optionally substituted C6-30 ar...  
WO/2019/020466A1
Process for the hydrolysis or alcoholysis of a ketal or acetal compound wherein a ketal or acetal compound comprising at least one ketal or acetal group and at least one amino group is reacted with carbon dioxide and water oran alcohol.  
WO/2019/009317A1
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.  
WO/2019/002371A1
A method of preparing a sterilized injectable hydrogel composition, comprising the steps: a) providing a covalently crosslinked glycosaminoglycan, b) swelling the covalently crosslinked glycosaminoglycan in a solution comprising Bis-Tris...  
WO/2018/228981A1
The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of -H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group,...  
WO/2018/227012A1
The present invention provides compositions (e.g., nanoparticles) comprising a conjugated polyethyleneimine (PEI) polymer (a "conjugated lipomer"), or a pharmaceutically acceptable salt thereof, and a lipid-PEG conjugate, wherein the con...  
WO/2018/224315A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst which contains one or more ...  
WO/2018/224316A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst containing Co, Ru and Sn.  
WO/2018/224321A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst obtained by reducing a cat...  
WO/2018/214877A1
Disclosed is a crystal form of dezocine. The X-ray powder diffraction (XRD) pattern thereof is determined using Cu/K-α1, and has a diffraction peak at the 2θ value of 9.1±0.2 and 12.2±0.2, and the height% of these diffraction peaks a...  
WO/2018/195956A1
Provided is a method for preparing a single crystal of an anhydrous halogenated choline or a derivative thereof, comprising the steps of: (1) proportionally weighing the halogenated choline or a derivative thereof, an alcohol or ether co...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/196860A1
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...  
WO/2018/200618A1
The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the ...  
WO/2018/191719A1
A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid),...  
WO/2018/191657A1
Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lip...  
WO/2018/185613A1
The present invention relates to an additive composition for controlling and inhibiting polymerization of monomers, wherein the composition comprises a combination of (a) a phenol compound comprising catechol compound with (b1) an alipha...  
WO/2018/181986A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/172133A1
Compounds of formula (I), wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to t...  
WO/2018/172026A1
The invention relates to a process for synthesizing an aqueous N,N-dimethyl glucamine solution, characterized in that a formaldehyde solution is metered into an N-methyl glucamine solution in the presence of a metal catalyst at hydrogen ...  
WO/2018/172025A1
The invention relates to a method for preparing aqueous solutions of N,N-dimethylglucamine, characterized by first preparing an adduct of N-methylglucamine and formaldehyde in water at temperatures of between 15°C and 40°C, and subsequ...  
WO/2018/148113A1
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditi...  
WO/2018/143923A1
The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups.  
WO/2018/135506A1
The purpose of the present invention is to provide a ruthenium complex which is capable of serving as a reduction catalyst that is applicable to an industrial production. According to the present invention, ketones, aldehydes, esters or ...  
WO/2018/129609A1
Compounds of formula (II) are useful in modulating voltage-gated sodium channel activity. Their preparation and use for reducing the severity of convulsant activity in a subject, for example in the treatment of epilepsy, is presented.  
WO/2018/127806A1
The present invention provides a process for preparation of isoproterenol hydrochloride (1a) comprising catalytic hydrogenation of 3',4'-dihydroxy-2-(isopropylamino)-acetophenone hydrochloride (5a) in presence of an ion exchange resin, t...  
WO/2018/129230A1
Synthetic methods for the preparation of ligands and metal-ligand complexes are disclosed.  
WO/2018/126040A1
The present invention is generally directed to crystalline forms of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-me thyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcy clohexanol and processes for their preparation.  
WO/2018/124148A1
The purpose of the present invention relates to providing a novel glyceric acid ester which can be produced at a high yield and for which use as a synthesis intermediate can be expected, and a method for producing same. The purpose of th...  
WO/2018/124149A1
The purpose of the present invention is to provide a method for producing glyceric acid ester that enables easy, high-yield production and makes it easy to reuse pyridines that are used for a reaction. Provided is a method for producing ...  
WO/2018/124147A1
The present invention relates to a method for manufacturing 1,3-dioxane-5-ones by a short and simple method from raw materials that can be obtained easily and inexpensively, using 1,3-dioxane, which is a mixture with 1,3-dioxalans, as a ...  
WO/2018/113581A1
Disclosed are a conjugate of dezocine and polyethylene glycol and a pharmaceutical composition thereof, wherein same have better pharmacokinetical properties and a high drug absorption degree, can decrease the side effects of drugs, and ...  
WO/2018/119263A1
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...  
WO/2018/108797A1
The invention relates primarily to a method for producing L-glufosinate or the salts thereof using ephedrine, in particular for producing L-glufosinate or the salts thereof by (dynamic kinetic) resolution of racemates. The invention also...  
WO/2018/108888A1
The invention pertains to a process for preparing hydroxyethyl ethylene amines and/or ethylene urea derivatives thereof comprising the step of reacting monoethylene glycol with an amine-functional compound comprising at least two -NH- un...  
WO/2018/108794A1
The invention relates to a method for producing D-glufosinate or salts thereof using ephedrine, in particular for producing D-glufosinate or salts thereof by (dynamic kinetic) resolution of racemates. The invention also relates to certai...  
WO/2018/108698A1
The invention relates to a method for producing ethanolamines and/or ethyleneamines in the gas phase by reacting ethylene glycol with ammonia in the presence of an amination catalyst. The method is characterized in that the amination cat...  
WO/2018/104176A1
The invention relates to a method for producing farnesyl amines by reacting ß-farnesene with one or more amines in the presence of a transition metal catalyst of the10th subgroup, at a temperature in the region of between 60 - 150 °C. (I)  
WO/2018/090982A1
Provided are a benzodicycloalkane derivative, and a preparation method and use thereof. In particular, provided is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method th...  
WO/2018/067685A1
Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.  

Matches 1 - 50 out of 7,795